Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWJ108J in Central Precocious Puberty
NCT06025409Phase 3Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
A Phase 3 trial of leuprorelin extended-release injection in central precocious puberty (CPP), sponsored by Daewoong Pharmaceutical. Status: unknown.
02
Drugs
leuprorelin extended-release injection
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT06025409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06025409.